Nr CAM is a marker for substrate‐selective activation of ADAM 10 in Alzheimer's disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Nr CAM is a marker for substrate‐selective activation of ADAM 10 in Alzheimer's disease ; volume:11 ; number:4 ; year:2019 ; extent:20
EMBO molecular medicine / European Molecular Biology Organization ; 11, Heft 4 (2019) (gesamt 20)
- Urheber
-
Brummer, Tobias
Müller, Stephan A.
Pan‐Montojo, Francisco
Yoshida, Fumiaki
Fellgiebel, Andreas
Tomita, Taisuke
Endres, Kristina
Lichtenthaler, Stefan
- DOI
-
10.15252/emmm.201809695
- URN
-
urn:nbn:de:101:1-2022081208474257889334
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brummer, Tobias
- Müller, Stephan A.
- Pan‐Montojo, Francisco
- Yoshida, Fumiaki
- Fellgiebel, Andreas
- Tomita, Taisuke
- Endres, Kristina
- Lichtenthaler, Stefan
Ähnliche Objekte (12)
Highly Substrate‐Selective Macrocyclic Ring Closing Metathesis
Biological markers of Alzheimer's disease
Substrate Rigidity Effect on CAD/CAM Restorations at Different Thicknesses
Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG Approach
Unmasking selective path integration deficits in Alzheimer’s disease risk carriers
Selective ferroptosis vulnerability due to familial Alzheimer’s disease presenilin mutations
Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate
CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
Novel 2-pheynlbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer’s disease
Memory markers in the continuum of the Alzheimer’s clinical syndrome
Evaluating frontoparietal network topography for diagnostic markers of Alzheimer’s disease
First ribbon growth on substrate (RGS) solar cells with selective emitter
Highly Substrate‐Selective Macrocyclic Ring Closing Metathesis
Biological markers of Alzheimer's disease
Substrate Rigidity Effect on CAD/CAM Restorations at Different Thicknesses
Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG Approach
Unmasking selective path integration deficits in Alzheimer’s disease risk carriers
Selective ferroptosis vulnerability due to familial Alzheimer’s disease presenilin mutations
Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate
CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
Novel 2-pheynlbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer’s disease
Memory markers in the continuum of the Alzheimer’s clinical syndrome
Evaluating frontoparietal network topography for diagnostic markers of Alzheimer’s disease
First ribbon growth on substrate (RGS) solar cells with selective emitter
Highly Substrate‐Selective Macrocyclic Ring Closing Metathesis
Biological markers of Alzheimer's disease
Substrate Rigidity Effect on CAD/CAM Restorations at Different Thicknesses
Neurophysiological Markers of Alzheimer’s Disease: Quantitative EEG Approach
Unmasking selective path integration deficits in Alzheimer’s disease risk carriers
Selective ferroptosis vulnerability due to familial Alzheimer’s disease presenilin mutations
Discovery of an enzyme and substrate selective inhibitor of ADAM10 using an exosite-binding glycosylated substrate
CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
Novel 2-pheynlbenzofuran derivatives as selective butyrylcholinesterase inhibitors for Alzheimer’s disease
Memory markers in the continuum of the Alzheimer’s clinical syndrome
Evaluating frontoparietal network topography for diagnostic markers of Alzheimer’s disease